Methotrexate treatment for refractory subacute cutaneous lupus erythematosus

J Am Acad Dermatol. 2002 Apr;46(4):600-3. doi: 10.1067/mjd.2002.114608.


Methotrexate is beneficial in rheumatoid arthritis and has been used in small studies of patients with systemic lupus erythematosus. We describe a patient with severe subacute cutaneous lupus erythematosus refractory to therapy with antimalarials and corticosteroids. Treatment with methotrexate resulted in complete clearing of the skin lesions without any side effects.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Female
  • Humans
  • Lupus Erythematosus, Cutaneous / drug therapy*
  • Lupus Erythematosus, Cutaneous / pathology
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*


  • Dermatologic Agents
  • Methotrexate